Mrs Chloe FERAL, INSERM, France
Based on Mrs. ChloĆ© FĆ©ral’s impressive credentials and contributions, she appears to be a highly suitable candidate for the Best Researcher Award.
Publication profile
Orcid
Research Excellence and Achievements
Current Position: Research Director (DR2) at INSERM, France, with significant roles in leading the “Epithelial homeostasis and tumorigenesis” team at IRCAN. Education: Acquired a PhD with honors and Habilitation (HDR), showcasing a strong foundation in Cell and Molecular Pharmacology. Awards and Fellowships: Received prestigious awards such as the Sanofi iAward and multiple grants from INCA and ARC, highlighting her contributions to translational research and cancer studies.
Research Contributions
Publications: Authored numerous high-impact journal articles, including in Scientific Reports, Cell Death & Differentiation, and International Journal of Molecular Sciences. Her research spans critical areas like epithelial homeostasis, tumorigenesis, and cancer biology. Patents: Holds a patent for methods and compositions for treating skin afflictions, demonstrating her innovative approach in research.
Leadership and Impact
Organizational Roles: Organized major scientific meetings and held several institutional responsibilities, such as serving on scientific advisory boards and council boards. Teaching Activity: Actively involved in teaching and training, including lecturing at prestigious institutions like the Ćcole Polytechnique Paris.
Scientific Community Engagement
Memberships and Committees: Engaged in various scientific societies and committees, contributing to the evaluation and guidance of research and academic activities.
Notable Research Highlights
Her work on epithelial stem cell fate and tumorigenesis, as well as advancements in cancer research, underlines her role as a leading figure in her field.
Awards
Dr. Chloe FERAL has been recognized for significant contributions in translational research. As Principal Investigator (PI), they led the Sanofi iAward EUROPE for Translational Research (2020-2021) and secured the PL-Bio Grant from INCA (2019-2023), collaborating with a team consortium. They also received the IDEX-UCAJEDI Prematuration grant from the University CĆ“te dāAzur (2019-2020). The Excellency Program from “La Ligue Contre le Cancer” (2014-2018) and the COPOC2018 Inserm Transfert Award (2018) further highlight their achievements. Additionally, Dr. [Name] received ARC Project Awards in 2016-2017 and 2018-2019. šš¬š§¬
Publication top notes